

Substitute Form PTO-1449 (Modified) <b>Information Disclosure Statement</b> <b>by Applicant</b> (Use several sheets if necessary) (37 CFR 1.98(b))	U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 119356-00055/4804US	Application No. 10/516,785
	Applicant Aladar A. Szalay et al.			
	Filing Date June 27, 2005		Group Art Unit 1636	

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	2005/0025745	02/03/05	Fujimori et al.	424	93.2	02/23/04

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AB	WO 04/069178	08/19/04	WIPO				
	AC	WO 00/23471	04/27/00	WIPO				
	AD	WO 00/71718	11/30/00	WIPO				
	AE	JP 09-502993	03/25/97	JP				X*
	AF	AU 709336	04/18/95	AU				

X\* = English language equivalent provided.

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AG	Demkowicz et al., "Human Cytotoxic T-Cell Memory: Long-Lived Responses to Vaccinia Virus," J. Virol. 70(4):2627-2631 (1996).
	AH	Lopez-Guerrero et al., "Therapeutic Effect of Recombinant Vaccinia Virus Expressing the 60-kd Heat Shock Protein on Adjuvant Arthritis," Arthr Rheum 37(10):1462-1467 (1994).
	AI	Orkin et al., "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy," (1995).
	AJ	Stienlauf et al., "Kinetics of formation of neutralizing antibodies against vaccinia virus following re-vaccination," Vaccine 17:201-204 (1999).

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	